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Abstract
Background: We examined the hypothesis that deficits in learning, memory, and other cognitive
functions are associated with the ε4 allele of the Apolipoprotein E (APOE) gene in a non-demented
sample with memory complaints recruited from a population with a high prevalence of this allele.
Methods: The study group comprised 70 consecutively referred patients aged 50–75 seeking
assessment due to memory complaints. They were screened for dementia, for neurological and
psychiatric disease, and for cerebral infarction using Magnet Resonance Imaging (MRI). Participants
were classified as non-demented based on clinical evaluation and results on cognitive tests.
Results: APOE ε4 carriers (56% of the sample) showed poorer performance than non-carriers on
the Mini Mental State Examination, a number of measures of verbal memory function from the
California Verbal Learning Test, and visual recall. In 46% of the participants, psychometric criteria
for amnestic Mild Cognitive Impairment (aMCI) were satisfied.
Conclusion: Findings may be partly explained by a significant number of participants being in a
preclinical phase of Alzheimer's disease. The observed deficits in learning performance and the lack
of significant age modulation of the genetic association suggest a more general genetic effect. The
findings are consistent with known neurobiological function of APOE ε4, including both increased
risk of neurodegenerative disease and reduced synaptic integrity in older age.
Background
Alzheimer's disease (AD) is the most prevalent form of
dementia in all age groups, with less than 1% incidence
before age 65, but with an exponential increase with age
[1]. Prior to diagnosis of AD many patients go through a
clinical phase termed mild cognitive impairment (MCI),
which has been characterized by subjective memory com-
plaints and clinical criteria of cognitive impairment with-
out being demented [2,3]. Memory may be the only
cognitive function affected (amnestic MCI), but MCI may
also affect other cognitive domains in isolation or in com-
bination with memory impairment [3]. Patients with MCI
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are shown to be at high risk of progression to AD [4].
However, non-demented elderly persons with subjective
memory complaints are found quite frequently in the
population at large and are a heterogeneous group.
Koivisto and collaborators [5] found a prevalence of 76%
in a randomly selected population sample aged 60–78
years, with the highest frequency in the younger part of
the sample. Studies of population prevalence of MCI in
similar age groups, using age adjusted psychometric crite-
ria of memory impairment, yield lower estimates, typi-
cally 2–5% [6,7].
The risk of developing AD is significantly increased by car-
rying one or more ε4 alleles of the Apolipoprotein E
(APOE) gene [8], and the risk increases in a dose depend-
ent manner in relation to debut of AD before age 70
[9,10]. APOE ε4 is also associated with reduced memory
function in clinically defined MCI patients [11]. Smith
and collaborators [12] studied a group of MCI patients
diagnosed on the basis of memory deficits and found that
APOE ε4 was associated with poorer performance on tests
of learning and recall in MCI patients, but not in normal
controls. They suggested that APOE-related memory defi-
cit is a specific cognitive phenotype in patients with AD
pathology. In a group of non-demented older adults,
Bondi and collaborators [13,14] found memory impair-
ment at study entry in APOE ε4 carriers, affecting meas-
ures of recall, recognition discriminability, and learning
slope as measured by the California Verbal Learning Test
(CVLT). No group differences between APOE ε4 carriers
and non-carriers were found in other cognitive domains.
Follow-up data [14] showed that a subgroup developed
dementia, and that the risk was related to APOE status and
memory performance at study entry.
APOE is a cholesterol transporting protein coded on chro-
mosome 19, with complex functions [15] that may affect
cognition and brain function in clinical as well as non-
clinical groups. A meta-analysis of population based stud-
ies by Small et al. [16] concluded that the ε4 allele is asso-
ciated with reduction in global cognitive functioning,
episodic memory, and executive functioning. Their results
revealed that APOE ε4 effects may vary with age, having a
larger impact in middle aged individuals than in the very
old. Longitudinal studies of elderly, healthy participants
have found that APOE ε4 was associated with more rapid
memory decline, but not with memory performance at
any given time of testing [17,18]. Mortensen and Høgh
[19] showed that the APOE ε4 allele was significantly
associated with a decline in tests of speeded attention and
visuo-construction in women, in particular those between
70 and 80 years of age. Evidence for an effect of APOE on
brain function in healthy individuals is reinforced by
studies using metabolic and functional brain imaging
techniques [20-22] and reaction time based attention
tasks [23,24].
The studies above indicate that the APOE ε4 allele may
affect cognition and brain function in both clinical and
non-clinical groups. Memory complaints are prevalent in
the middle aged population, and the risk for developing
AD based on memory complaints alone is low. The pro-
portion of study participants with ε4 allele will also vary
with recruitment and inclusion criteria in relation to base
rates in the general population. Although APOE ε4 has
been shown to be a risk factor for AD in many popula-
tions, the APOE ε4 - AD association was shown to be
weaker among African Americans and Hispanics than in
Caucasians and Japanese [10,25]. The prevalence of ε4
alleles also varies significantly between European popula-
tions, from a low incidence (10–15%) of ε4 alleles in
southern European populations to a high incidence (40–
50%) in northern European populations [26]. The func-
tional consequences of the genetic variation have not
been fully explored. One consequence might be a differ-
ence in incidence of early debut of AD between southern
and northern European countries. This has not been con-
firmed by comparative epidemiological studies (ERO-
DEM) [27], but methodological differences across the
studies preclude definite conclusions.
In the present study we examined neuropsychological per-
formance associated with variants of APOE alleles in non-
demented middle aged and older Norwegian participants,
who are part of a population with high incidence of APOE
ε4. Earlier studies have reported a high prevalence of sub-
jective memory complaints in 60–70 year olds [5] and a
low risk of developing AD before age 75 [28]. This indi-
cates that a clinically recruited non-demented group of
participants younger than 75 years will include a signifi-
cant proportion of participants with age related reduction
of cognitive functions that are not primarily due to degen-
erative pathology. Based on the high prevalence of ε4 alle-
les in the Norwegian population [26], we expected a high
incidence of these alleles in our study group, and we asked
if the pattern of cognitive function confirmed the results
in samples from populations with lower base rates of ε4.
Methods
Patients
Participants were referred by their primary physician to a
clinical research project on age related cognitive impair-
ment and risk for dementia at the Department of Neurol-
ogy, Buskerud Hospital, Drammen, Norway. Only
patients in the age range 50–75 years were candidates for
the project. Each individual underwent an extensive
assessment based on the Consortium to Establish a Regis-
try on Alzheimer's Disease (CERAD) protocol [29],
including a comprehensive neuropsychological investiga-Behavioral and Brain Functions 2007, 3:57 http://www.behavioralandbrainfunctions.com/content/3/1/57
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tion that was supplemented by the Norwegian version of
the CVLT [30]. All patients underwent full neurological
and medical examination, including Magnet Resonance
Imaging (MRI) brain scan and laboratory tests. Inclusion
criteria were complaints of memory problems of at least 6
months duration, an estimated IQ score >80, and a score
of 24 or higher on the Mini Mental State Examination
(MMSE) [31]. Patients with a neurological, psychiatric, or
another diagnosis which might affect cerebral function
were excluded as well as patients with a known history of
alcohol or substance abuse. All cases were reviewed by a
panel including a neurologist and a neuropsychologist
after completion of the study protocol, and patients who
received a dementia diagnosis according either to the
DSM-IV [32] or the ICD-10 [33] criteria were excluded.
The final sample included in the present study consisted
of 70 individuals, 33 men and 37 women. The average age
was 63.9 years (SD = 7.7). All participants had completed
obligatory basic education (7 years in this cohort). The
average number of years of education for the sample was
11.2 years (SD = 3.0), the average IQ was 106 (SD = 14),
and the sample's average MMSE score was 27.89 (SD =
1.78). All individuals were living independently at the
time of participation in this study. The study was per-
formed according to the Declaration of Helsinki [34] on
guidelines for biomedical research involving human sub-
jects.
Apolipoprotein E
The APOE genotype was determined with polymerase
chain reaction (PCR) according to standard methods.
Individuals were classified as APOE ε4-positive (ε4 carri-
ers) or APOE ε4-negative (non-carriers) based on the pres-
ence or absence of at least one ε4 allele. The ε4 carrier
group (56% of the study group) comprised 39 patients,
with allele combinations ε 2/4 (n = 4), ε 3/4 (n = 24) and
ε 4/4 (n = 11). Thus, 16% of the sample was ε 4/4
homozygote. In the non-carrier group of 31 patients the
allele combinations were ε 2/3 (n = 4) or ε 3/3 (n = 27).
No patient had the allele combination ε 2/2.
Neuropsychological tests
The neuropsychological test battery was administered
according to the CERAD protocol [29]. Main areas of cog-
nitive functioning were assessed. The areas and test meas-
ures are shortly described below. For a more detailed
description, see [35]. Since impaired performance on ver-
bal memory acquisition and recall have been demon-
strated particularly sensitive measures to discriminate
between ε4 carriers and non-carriers and in addition are
well known markers for identifying early stages of AD
[13,14], we considered specific measures on tests of verbal
memory function as primary outcome measures (i.e. total
learning score, short and long delay free recall (all from
the CVLT), Verbal Paired Associate Test – learning and
recall). All other scores were regarded as background vari-
ables.
Intellectual function
Two subtests (Vocabulary and Matrix Reasoning) from the
Norwegian version of the Wechsler Abbreviated Scale of
Intelligence (WASI) [36] were administered to estimate an
IQ score. In the Vocabulary subtest, participants were
asked to define orally presented words. In the Matrix Rea-
soning subtest, incomplete patterns were presented and
the participants were asked to complete the patterns by
pointing to one of five available response alternatives.
Memory function
The California Verbal Learning Test (CVLT) [37] was
included to obtain measures of verbal learning, recall and
recognition, as well as learning strategies, error types, and
serial position effects. In the learning task, the participants
were presented to a list of 16 words (list A), where each
word belonged to one of four categories. The list was pre-
sented and recalled five times before a second list (list B)
was presented. The participants were immediately after
the recall of list B asked to recall the words from list A,
both in a free and cued recall condition. After an interval
of 20 minutes, the participants were again asked to recall
the words from list A in a free and cued recall and recog-
nition condition. The Verbal Paired Associates Test [38]
was included as another measure of verbal learning and
memory function. 15 word pairs were presented, and the
number of recalled pairs was recorded.
The Rey Complex Figure Test (RCFT) [39], recall condi-
tion, was included as a test of visual memory function.
The participants were asked to copy the Rey-Osterrieth fig-
ure (a visuo-constructive task). After an interval of 20 min-
utes, the participants were then asked to draw the figure as
they remembered it from the copy-task.
Attention and psychomotor speed
Two visuo-motor tests of attention and psychomotor
speed were included, the Digit Symbol Test [40] and the
Trail Making Test A [41]. In the Digit Symbol Test, a sheet
containing rows of blank squares were presented, each
square being paired with a randomly assigned number
(1–9). The task was to fill in as many blank squares as pos-
sible within 90 seconds. In the Trail Making Test A, the
participants were requested to draw lines to connect con-
secutively numbered circles (1–25) as fast as possible. The
time to complete the tasks was recorded.
The Trail Making Test B [41] was included as a measure of
cognitive flexibility. The participants were asked to draw
lines to connect circles by alternating between circles with
numbers and letters (1-A-2-B etc.). The time to complete
the test was recorded. The third subtest of a Stroop ColorBehavioral and Brain Functions 2007, 3:57 http://www.behavioralandbrainfunctions.com/content/3/1/57
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Word Test [42] was used as a measure of cognitive flexibil-
ity/inhibition. In the first subtest, the participants were
asked to name color patches (1), then to read color words
(2), and in the third condition to name the color of color-
words printed in an ink of a different color (3) as fast as
possible. Time to complete the tasks was recorded.
Verbal function
Fluency of speech was assessed using the Controlled Word
Association Test (COWAT)[43]. Participants were asked to
name as many words as possible with a given first letter
within one minute, using the letters F, A, and S. After-
wards, participants were asked to name as many animals
as possible within a minute. The Boston Naming Test was
used to provide information about ease and accuracy of
word retrieval. 15 items of the Boston Naming Test [44]
were presented, including five words with low, medium
and high frequency of occurrence, respectively.
Subjective memory complaints
A standardized interview was performed by the examining
physician, according to a Norwegian translation of the
CERAD Clinical History protocol. The information
obtained from the patient was scored by the physician at
the time of the interview. In addition to the two items on
memory complaints and their impact on everyday life, the
protocol itemized 7 specific domains of non-memory
complaints.
Amnestic MCI
Amnestic MCI (aMCI) was defined when a participant
obtained a result on the long delay free recall CVLT subtest
that was at least 1.5 standard deviations (SD) below the
age and gender adjusted norm. These norms are the stand-
ard norms presented by the test-developers [37].
MRI protocol
Magnet Resonance Imaging (MRI) was included to detect
and exclude patients with gross morphological changes.
Imaging was initially performed with a 0.5 T Philips scan-
ner, replaced at a later stage with a Philips 1.0 T scanner.
Standard T1 and T2 clinical scanning sequences were used
and visually rated from a hard copy by the departmental
chief radiologist, who was blinded with regard to other
study parameters [45].
Data analyses
For all statistical analyses, SPSS version 14.0 was used
[46]. Independent samples t-tests were used to test the dif-
ferences in demographic characteristics of the ε4 carrier
and non-carrier groups. Categorical data was analyzed
using chi-square test. When data met the assumption of
normality, independent samples t-tests were used to
examine group differences on neuropsychological meas-
ures. When basic assumption for parametric tests, i.e. nor-
mal distribution, was violated, Mann-Whitney U
nonparametric tests were used. These analyses were com-
pleted with calculations of effect sizes, i.e. Cohen's d for
parametric tests and r as an approximate effect size when
nonparametric tests were utilized. Additionally, repeated
measures ANOVAs were used to assess general effects of
learning, retention and recall, respectively. Learning was
assessed by entering the performance on learning trial 1 to
5 as within subject variables. Retention was examined by
entering learning trial 5 and the delayed free recall score,
and the recall measure included the scores on the short
delay and long delay free recall subtests as within subject
variables. All analyses tested interaction effects of geno-
type with gender and of genotype with age. The sample
was split by the median (65 years) into two age groups,
entering age and genotype as fixed factors. In case of a sig-
nificant group effect between ε4 carriers and non-carriers,
the dose effect was explored by comparing the results in ε4
homozygotes and ε4 heterozygotes. All statistical tests
were two tailed. The alpha level was generally set at 0.05.
Since several measures of cognitive functioning were
included, it seemed appropriate to control for Type I error
rate for the primary outcome measures, i.e. the measures
of verbal memory function. For those analyses, correcting
according to Bonferoni, a p value of 0.01 was regarded as
statistically significant.
Results
The demographic characteristics of the ε4 carriers and
non-carriers are shown in Table 1. There were no signifi-
cant group differences in age, education, or gender distri-
bution between the group of ε4 carriers and non-carriers.
MRI findings were noted in 67% of non-carriers and 71%
of ε4 carriers. The frequency of MRI findings was not sig-
nificantly different between the groups. The most frequent
finding was subcortical hyperintensities, reported in 57%
Table 1: Demographic characteristics in APOE ε4 carriers and non-carriers
non-carriers (n = 31) ε4-carriers carriers (n = 39) t-values p-values
M (SD) M (SD)
Age at test 62.9 (8.81) 64.7 (7.15) -0.979 0.331
Years of education 11.4 (3.11) 10.8 (2.98) 1.123 0.266
Sex (M/F) 16/15 17/22 0.631*
* Chi-square test statisticBehavioral and Brain Functions 2007, 3:57 http://www.behavioralandbrainfunctions.com/content/3/1/57
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of the non-carriers and 47% of the ε4 carriers. Cortical or
subcortical atrophy was found in 20% of the non-carriers
and 27% of the ε4 carriers.
Subjective memory problems of at least 6 months dura-
tion were present in all patients, and more than half of the
sample (57%) reported duration of memory problems
longer than 2 years. Typical mode of onset was gradual
progression (59%), but 13% reported that the impair-
ment had been stable, and the rest reported a fluctuating
course. ε4 carriers did not complain of more severe mem-
ory problems or of having more non-memory cognitive
problems than the non-carriers.
There were no statistically significant differences between
the group of ε4 carriers and non-carriers on tests of intel-
lectual function, verbal function, attention/psychomotor
speed and visuo-constructive function (Table 2). There
was, however, a significant difference in the MMSE score
between the APOE groups, showing that ε4 carriers
obtained a statistically significant lower performance
score than the non-carriers (p = 0.032). Follow-up calcu-
lation of Cohen's d revealed an effect size of (d = 0.53),
representing a medium sized effect according to Cohen's
definition [47]. Statistically significant differences
between the two APOE groups were also found on Boston
Naming Test (p = 0.03, r = -0.26) and the RCTF-recall
measure (p = 0.02, r = -0.27).
ε4 carriers showed lower performance than non-carriers
on several CVLT measures, as shown in Figure 1 and Table
3. Group differences became statistically significant only
for Learning trial 1 but for none of the other comparisons;
however, effect sizes revealed small to medium effects for
several measures.
Learning measures
A repeated measures ANOVA, including the five CVLT
learning trials, showed that the non-carriers showed an
overall better learning performance than ε4 carriers (F
(1,68) = 5.46, p  = 0.022). There was no interaction
between group and learning trial. On average, participants
in both APOE groups recalled more items on trial 5 than
on trial 1. Consistent with this finding, the APOE groups
showed no significant difference in slope of the learning
curve, characterizing performance increment across trials
(Figure 1). To explore strategies used in the learning proc-
ess, we compared semantic and serial clustering, recall
consistency, and serial position effects in the two APOE
groups (Table 3). ε4 carriers showed a significantly lower
consistency across learning trials (MW, p = 0.01, r = -0.3)
as well as significantly more intrusions in the learning tri-
als (MW, p = 0.03, r = -0.25). There was no significant dif-
ference between the groups regarding clustering strategies
and serial position effects.
Recall and rate of forgetting
A repeated measures ANOVA, entering the short delay free
recall and long delay free recall scores from CVLT as
within-subject factors, showed no statistically significant
difference between the two APOE groups.
An analysis of the rate of forgetting, including the learning
trial 5 and the delayed free recall score from CVLT as
between subject factors, showed no statistically significant
APOE group difference.
Recognition
Mann-Whitney nonparametric tests were used to analyze
the differences between ε4 carriers and non-carriers on
recognition measures. The only significant difference
Table 2: Mean performance (SDs shown in parantheses) of APOE ε4 carriers and non-carriers on cognitive measures (raw scores)
ε 4 non-carriers (n = 31) ε 4 carriers (n = 39) t-values/U-values p-values Effect sizesa
MMSE 28.4 (1.6) 27.5 (1.8) 2.19c 0.03 0.53
WASI-IQ 105 (13.4)b 106 (15.3)b 0.068c,e 0.95 0.01
Stroop Color Word Test (seconds) 94 (54.3) 106 (58.0) -0.840c 0.40 0.22
WAIS-R Digit Symbol (items) 35 (10.5) 32 (12.1) 1.166c 0.25 0.27
FAS (items) 30 (12.0) 31 (12.8) -0.262c 0.79 0.08
Animal fluency (items) 16 (5.8) 17 (5.6) -0.299c 0.77 0.18
Trail Making A (seconds) 48 (22.0) 58 (26.9) 477d 0.13 -0.18
Trail Making B (seconds) 144 (112.6) 165 (89.4) 479.5d 0.14 -0.18
Boston Naming (items) 15 (1.1) 14 (1.1) 539.5d 0.03 -0.26
Rey Complex Figure Test – copy (points) 33 (5.4) 31 (7.0) 487d 0.16 -0.17
Rey Complex Figure Test – recall (points) 16 (9.0) 11 (7.5) 410.5d 0.02 -0.27
Degrees of freedom for all parametric tests was 68
a For t-tests, Cohen's d, for nonparametric tests r were calculated
b Standardized scores
c Test statistics according to independent t-tests
d Test statistics according to Mann-Whitney U tests
e Test statistic based on age-adjusted scoresBehavioral and Brain Functions 2007, 3:57 http://www.behavioralandbrainfunctions.com/content/3/1/57
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appeared for the false alarm scores (MW, p = 0.02, r = -
0.27).
Effects of gender, age, and dose on cognitive performance
To examine modulating effects of gender and age on CVLT
performance, we performed repeated measures ANOVAs
including APOE status and gender as between subject fac-
tors and learning trial 1 to trial 5 as within subject factors.
Even though several mean values indicated that women
performed better than men, the analysis revealed no sta-
tistically significant interaction effect of APOE status and
gender (F (1,68), p = 0.09). When rerunning the analysis
by including age and APOE status as between subject fac-
tors, no statistically significant effect (F (1,68), p = 0.52)
was demonstrated. The analyses of dose effects showed no
statistically significant differences between homozygotes
and heterozygotes for ε4 on any measure of learning and
memory function.
aMCI
There were 32 participants who were allocated to the
group of aMCI according to our definition (i.e. a free
recall performance at least 1.5 standard deviations below
normative mean), 6 homozygotes, 18 heterozygotes and
8 non-carriers of the ε4 allele. Test statistics revealed a sta-
tistically significant higher number of ε4 carriers than
non-carriers in this aMCI group (χ2 = 4.06, p = 0.04). The
average age in the aMCI group was slightly higher (M =
65.1, SD = 8.1) than the non-aMCI group (M = 62.8, SD =
7.3), but the difference was not statistically significant (t =
-0.236,  p  = 0.221). However, individuals in the aMCI
group performed significantly lower on the MMSE (aMCI
M = 27.3 (SD = 1.7), non-aMCI M = 28.4 (SD = 1.7), t =
2.58, p = 0.01) and had a lower IQ score (aMCI M = 101
(SD = 11.9), non-aMCI M = 110 (SD = 15.1), t = 2.61, p =
0.01). There was no statistically significant group differ-
Mean number of words on the five learning trials from the  CVLT in APOE ε4 carriers and non-carriers Figure 1
Mean number of words on the five learning trials from the 
CVLT in APOE ε4 carriers and non-carriers. * indicates p = 
0.04.
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Table 3: Mean learning and memory performance (raw scores) on the Verbal Paired Associate Test and the California Verbal Learning 
Test (CVLT) in APOE ε4 carriers and non-carriers (SDs shown in parantheses)
ε 4 non-carriers ε 4 carriers t-values/ U-values p-values Effect sizesa
(n = 31) (n = 39)
*Verbal Paired Associate Test – learning (errors) 33 (22.7) 41 (22.2) -1.51c 0.14 0.52
*Verbal Paired Associate Test – recall (errors) 7 (4.2) 9 (4.8) -1.80c 0.08 0.63
CVLT
List A Trial 1 recall 5.8 (2.6) 4.6 (2.2) 2.14b 0.04 0.51
List A Trial 5 recall 10.1 (3.8) 8.5 (3.3) 1.85b 0.07 0.46
*Total learning (trial 1–trial 5) 42 (15) 34.7 (11) 2.34b 0.02 0.57
*Short delay free recall 7.3 (4.3) 6.1 (3.9) 1.20b 0.24 0.30
Short delay cued recall 9.3 (3.8) 8.1 (3.4) 1.35b 0.18 0.34
*Long delay free recall 8.5 (4.3) 6.8 (3.9) 1.78b 0.08 0.44
Long delay cued recall 9.1 (3.5) 8.1 (3.5) 1.18b 0.24 0.29
Percent recognition discriminability 89 (10.1) 84 (11.4) 1.84b 0.07 0.47
Intrusions learning 0.3 (0.7) 0.8 (1.4) 467c 0.03 -0.25
Short delay intrusions 0.2 (0.5) 0.3 (0.6) 559.7c 0.45 -0.09
Long delay intrusions 0.4 (0.6) 0.7 (1.5) 545c 0.39 -0.10
Recognitions hits 14.3 (1.8) 13.9 (1.9) 521.5c 0.32 -0.12
Recognition false alarms 3.0 (4.3) 4.7 (4.2) 413.5c 0.02 -0.27
Response bias (recognition) 0.09 (0.4) 0.24 (0.4) 462c 0.09 -0.20
Percentage consistency 75.7 (17.1) 67.6 (15.9) 395c 0.01 -0.30
Degrees of freedom for all parametric tests was 68
* According to Bonferoni correction, a p-value of 0.01 was regarded as significant for these scores
a For t-tests, Cohen's d, for nonparametric tests r were calculated
b Test statistics according to independent t-tests
c Test statistics according to Mann-Whitney U testsBehavioral and Brain Functions 2007, 3:57 http://www.behavioralandbrainfunctions.com/content/3/1/57
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ence with respect to educational level (aMCI M = 10.4 (SD
= 2.7), non-aMCI M = 11.8 (SD = 3.2), t = 1.85, p = 0.07).
Discussion
Results from the present study showed that the APOE ε4
carriers showed a statistically significant lower perform-
ance on a number of measures of verbal learning and
memory than the non-carriers. Performance of the ε4 car-
riers on the CVLT was characterized by fewer correctly
reported words on all learning trials, reduced between-
trial recall consistency, a higher number of intrusions dur-
ing learning trials, and an increased frequency of false
alarms in recognition trials than the non-carriers. Recall of
the verbal material across varying delays was not dispro-
portionately reduced in the ε4 carriers, but further statisti-
cally significant differences between the two groups were
demonstrated for the Boston Naming Test, the recall
measure of the RCFT, and on the MMSE. Gross measures
of cerebral atrophy or subtle vascular pathology on MRI
could not distinguish between ε4 carriers and non-carri-
ers, and the level of subjective complaint of memory prob-
lems was not significantly related to APOE status.
According to the selected criteria for MCI, 46% of the par-
ticipants were classified as aMCI. The aMCI group showed
an increased frequency of ε4 alleles than the non-MCI
group.
The results were generally in accordance to those in previ-
ous studies of clinically recruited aging participants,
showing that APOE ε4 is associated with impaired per-
formance on subtasks from the CVLT [13,14]. There were,
however, differences in the profile of test results between
the study groups. Bondi et al. [14] found that reduced
delayed recall and learning slope discriminated well
between the APOE groups, whereas our results indicated
that a pattern of inconsistent retrieval and erratic report-
ing (intrusions of non-presented words) characterized the
learning and memory function in ε4 carriers. In spite of
the fact that the CVLT measure of long delay recall has
shown to be sensitive to early changes of AD in other stud-
ies [13,14,48], the two APOE groups showed similar
results in the our study. This might be due to the lack of
statistical power because of the small sample size in the
present study. This argumentation was supported by
medium effect sizes on scores such as long delay free recall
(CVLT) and the Verbal Paired Association Test (learning
and recall). Furthermore, the age range in the present sam-
ple may have influenced our results. The participants were
on average 7 years younger than the ones studied by
Bondi et al. [14] (64 years vs. 71 years). We suggest that
the younger age of the participants in the present study
may partly explain why their memory performances were
less characteristic of mild AD than the patient group stud-
ied by Bondi et al. [14]. Even if several studies concur that
measures of delayed recall are predictive of risk for devel-
oping dementia [14,48], other have found that measures
of learning are equally or more predictive [49,50]. How-
ever, the distinction between learning and recall may not
be very informative since episodic memory is critically
involved both in learning performances across repeated
trials and in delayed recall.
In the present study, the APOE status was found to have a
significant effect on the recall measure from the RCFT.
This was not found in the Bondi et al. [14] study, although
the performance on another visual memory test (Wechsler
Memory Scales, visual reproduction) showed a trend
towards lower scores in ε4 carriers. Other studies of ε4 car-
riers which have included the RCFT have shown mixed
results [51,52], and our finding was in accordance with
the study of Caselli et al. [18], showing lower delayed
recall sores for ε4 carriers on a complex figure test.
An atypical finding in our study was the poorer perform-
ance of the ε4 carriers on the first presentation of the word
list. This may be explained as an attention deficit, a word
finding or semantic deficit, or a memory problem. Per-
formance on the Boston Naming Test differed signifi-
cantly between ε4 carriers and non-carriers, which could
suggest a word retrieval problem. However, we believe
that this was not the case since both groups obtained
results that were more than one standard deviation above
age-corrected norms (not shown data) and no other meas-
ures of verbal function (Vocabulary, animal and letter flu-
ency) confirmed such a problem in the ε4 carriers.
Together with the lack of group differences on the remain-
ing tests of attention (Digit Symbol Substitution, Trail
Making Test, Stroop Color Word), we suggest a selective
memory problem in the ε4 carriers.
The significant lower performance of ε4 carriers than the
non-carriers on the MMSE deserves a comment, because
such a finding could indicate that ε4 carriers showed gen-
eral lower cognitive functioning than the non-carriers. We
argue against such a conclusion, in that the two groups
performed almost equal on the comprehensive neuropsy-
chological test battery, expected to be at least as sensitive
to impairment as the MMSE. Furthermore, the MMSE dif-
ference was less than one point and all participants
obtained a MMSE score above 24.
It may be argued that the displayed problems in the ε4 car-
riers are a consequence of the inclusion of patients with
subjective memory problems. This argument may have
some merit if the study population is defined on the basis
of reduced performance on memory tests, as is the case in
some definitions of MCI [3]. In the present study, we
included participants on the basis of widely defined clini-
cal criteria based on subjective cognitive complaints, with
symptoms and pathological markers of dementia as exclu-Behavioral and Brain Functions 2007, 3:57 http://www.behavioralandbrainfunctions.com/content/3/1/57
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sion criteria. In view of the high incidence of subjective
memory complaints in the general population [5], it is
likely that patients recruited on the basis of this criterion
will include a heterogeneous group of normal and mildly
pathological cases. Our results confirmed that subjective
memory complaint is not associated with APOE status
[53], and Fisk et al. [6] found that eliminating the crite-
rion of subjective memory complaint from the definition
of MCI had no impact on the relative risk of subsequent
cognitive decline. Therefore, it is less likely that subjective
memory complaint has served as a strong factor biasing
the findings of an association of memory dysfunction and
APOE ε4 in the present study.
Despite the relatively young age of our sample, 46% of the
patients satisfied psychometric criteria for aMCI. This
group showed an increased frequency of APOE ε4 alleles,
and data from other studies [3,54] suggest that the aMCI
group has an increased risk of developing AD. Thus, the
association between APOE status and memory perform-
ance may be explained by the presence of a significant
number of preclinical AD patients in the study popula-
tion. This was also the conclusion drawn by Bondi et al.
[13,14] on the basis of follow-up data for their sample.
We acknowledge that this is a likely explanation for part
of our findings. Although these authors showed that the
combination of impaired memory performance and
APOE  ε4 genotype had a high predictive value in the
course to AD, this has not always been confirmed [49,55].
It is important to note that in the present study, 25% of
the participants classified as aMCI were non-carriers. This
possibly reduces their risk to progress to AD. Furthermore,
this points to an important weakness of the concept of
MCI. A number of authors have demonstrated that elderly
individuals showed fluctuating performance when
assessed with neuropsychological tests [56], and that
there are individuals classified as MCI who remained sta-
ble or even re-obtained normal cognitive function on fol-
low-up [57]. In our group, other reasons than underlying
neurodegenerative processes could have lead to classifica-
tion as aMCI. In the present study, the group of individu-
als defined as aMCI had significant lower IQ scores and
lower scores on the MMSE. Thus, some of individuals in
the aMCI group may have been misclassified due to a gen-
eral low cognitive abilities or a more a temporary cogni-
tive impairment.
Proximity to a likely age of debut for AD is expected to be
a powerful factor predicting memory deficit. Although the
average age for the aMCI group was somewhat higher than
the remaining group, we did not find that age as such was
a significant modulator of the relation between APOE sta-
tus and memory performance. Homozygozity for ε4 has
been shown to confer another significant increase in risk
for conversion to AD, but this was not confirmed by the
results in the present study. In this respect our results
resemble those of Caselli et al. [17] in a normal group in
an age range similar to ours. In accordance with Caselli's
group [18,58] we noted that while the definition of aMCI
emphasizes a memory profile resembling mild AD with
reduction in delayed recall, this was not the pattern of
memory performance that best characterized the differ-
ence between ε4 carriers and non-carriers in the present
group. Based on all these observations we assume that the
whole study group rather than a subgroup with early AD
has contributed to the results in the present study. While
the APOE ε4 related mechanisms that are not explicitly
linked to AD pathology [15] are thought to affect neuro-
nal health in general, it is likely that memory and learning
are domains of cognitive function that are more sensitive
to impaired synaptic plasticity than other domains. More
sensitive and specific tests of attention, as shown by
Greenwood and Parasuraman using a cued visual discrim-
ination task [23], may also reveal effects in this domain.
Even though we used Bonferoni correction for a number
of analyses, this study can be criticized for the use of mul-
tiple comparisons since some of the neuropsychological
measures surely tap the same cognitive resources. This and
the small sample size request caution when interpreting
the results until these are verified by further North Euro-
pean studies. Another issue is the clinical impact of our
findings. In the present study, the aim was to investigate
group differences rather than individual patterns of cogni-
tive function. Although group results give indications to a
clinician, he or she will still have to assess their patients
individually to take into account the individual differ-
ences in older adults. Follow-up studies are necessary to
answer the question of the predictive value of cognitive
decline in patients with APOE ε4 in Nordic samples and
characteristics of different developmental pathways.
Conclusion
The present study of consecutively referred non-demented
patients included 55% of participants with at least one ε4
allele, and 15 % of the total sample were ε4 homozygotes.
The proportion is high in comparison with MCI samples
[4] and with unselected AD cases [59], which reflect the
fact that the general population from which the present
patients were recruited also has a high incidence of ε4 alle-
les [26]. While APOE has been commonly accepted as a
susceptibility gene for late onset AD, with increased risk
associated with the ε4 allele, it has also become increas-
ingly clear that genetic risk is modulated by other factors.
There is increasing information of gene combinations that
may serve to modify APOE effects [24,60]. While the
present findings are largely consistent with reports based
on North American and European populations, further
comparative studies of effects on cognition of APOE and
other genes may give information relevant to focusing onBehavioral and Brain Functions 2007, 3:57 http://www.behavioralandbrainfunctions.com/content/3/1/57
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APOE. mechanisms as a therapeutic target. Exploiting the
natural variation in prevalence of at-risk alleles is an
important part of this strategy.
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